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Abstract Medulloblastomas comprise the most frequent
malignant brain tumor in childhood and one of the biggest
challenges in pediatric oncology. The current concept sug-
gests that these tumors may undergo stepwise progression
as it has been shown for other brain tumors. However, con-
clusive evidence of molecular progression over time has
not been demonstrated yet for medulloblastoma. In the
present study, 28 pairs of medulloblastoma at primary diag-
nosis and at the time of recurrence, either occurring as local
tumor regrowth or tumor dissemination, were histopatho-
logically and molecularly analyzed. Cytogenetic analysis
included interphase Xuorescence in situ hybridization for
Wve genomic loci (MYC, MYCN, 17p, 17q, 6q) that have
previously been identiWed as prognostic markers in primary
tumors. Of 16 tumors showing early recurrence (<4 years
after Wrst diagnosis), only one showed increased histological
anaplasia in the secondary lesion (6%), and two acquired
genomic lesions indicative for a more malignant phenotype
(13%). In contrast to this, of 12 tumors with a time to recur-
rence of 4 years or more, nine tumors (75%) showed a more
malignant phenotype either reXected by increased anaplasia
alone or by both increased anaplasia and acquirement of
genomic aberrations known to be associated with inferior
patient outcome. These results suggest that early recurrence
in medulloblastoma mainly occurs in tumors with a highly
malignant genotype and phenotype per se, whereas late
recurrence is often dependent on tumor evolution toward a
more malignant biology. Therefore, biopsy of recurrent
tumors should be performed to assess the biologic proper-
ties of the relapsed tumor, especially when targeted therapy
approaches are considered.
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Introduction
Brain tumors are the leading cause of cancer-related mor-
tality in pediatric patients, with medulloblastoma (MB)
being the most common representative in this age group.
Considerable advances have been made in the treatment of
MB in the last three decades by using multimodal therapeu-
tic regimens involving surgery, radiotherapy, and chemo-
therapy. About 10–15% of patients die from disease within
2 years after diagnosis, whereas approximately 60% of
patients can nowadays be cured [9, 11, 22, 23]. However,
the predictive performance of current risk stratiWcation,
which is entirely based on clinical variables, needs to be
improved because of the dismal prognosis of children with
tumor relapse, and because of relevant treatment-induced
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based on age, metastatic stage at diagnosis and, in some
studies, extent of surgical resection have so far been the
most useful methods for the stratiWcation of patients into
standard and high risk therapy groups [1, 26, 27]. Addition-
ally, after reWnement of the histological classiWcation
of MB in the 2007 WHO classiWcation, the histological
subtype is of potential prognostic relevance: large cell/ana-
plastic MB behaves more aggressively, while nodular/
desmoplastic variants show a more favorable clinical
course as compared to the large group of classic MB [3, 5,
7, 10, 13, 14, 17]. Some recent studies have extended the
concept of anaplasia in MB and suggested that this phe-
nomenon reXects malignant progression of a tumor and
may occur in various MB subtypes independent of large
cell histology [3, 4, 12]. Progression over time from non-
anaplastic to anaplastic MB has been described in cases
with local tumor recurrence [3, 12] as well as in secondary
metastatic lesions with or without local recurrence [4].
To date, numerous molecular studies have highlighted
various chromosomal aberrations in MB, and some of them
were found to be associated with clinical outcome. Cytoge-
netic aberrations in MB involving chromosome 17 as well
as ampliWcations of the MYC or MYCN oncogenes have
previously been associated with large cell histology and
poor patient survival in diVerent studies [6, 7, 9, 11, 13, 15,
17, 18, 23, 24]. In contrast, several recent reports have
identiWed monosomy of chromosome 6 to be associated
with consecutive WNT pathway activation and favorable
clinical outcome [2, 8, 25].
Nevertheless, in contrast to astrocytomas and oligoden-
drogliomas, molecular progression of MB has only been
suspected, but has not been unanimously proven. A step-
wise progression of genetic abnormalities in these tumors
was identiWed in a few cases only, when comparing primary
and recurrent tumor specimens [3].
Here, we performed comparative histopathologic and
cytogenetic analyses of 28 MB cases, for which samples
from primary manifestation and tumor recurrence were
available. The aim of this study was to determine which his-
topathological features and chromosome abnormalities may
be associated with MB molecular progression over time.
Interphase Xuorescence in situ hybridization (FISH) was
carried out for Wve regions of interest, namely MYC, MYCN,
chromosome 6q, and chromosomal arms 17p and 17q.
Materials and methods
Patient population
Specimens from 28 MB patients who experienced disease
recurrence were analyzed in this study. All these patients
had received reoperations at secondary diagnosis and
specimens from primary and subsequent interventions
were available for comparative histopathological and
molecular analyses. Patient details are outlined in
Table 1. There were 21 males and 7 females, and age
ranged from 3 to 37 years (median 14 years). Sixteen
patients experienced early recurrence (<4 years after Wrst
diagnosis), and 12 patients had a time to recurrence of
48 months or more (late recurrence). Staging procedures
included MRI before and immediately after neurosurgery.
Metastatic disease was detected by craniospinal imaging
and analysis of the cerebrospinal Xuid following the
Chang classiWcation. Most of the patients (26) had no lep-
tomeningeal tumor dissemination (i.e. M0 stage) at the
time of primary diagnosis. All patients were treated
according to a standard treatment protocol, consisting of
surgical tumor resection, followed by craniospinal irradi-
ation with 36 Gy and a boost to the posterior fossa adding
up to a total dose of 53–56 Gy, and eight cycles of vincri-
stin, lomustine, and cisplatin. Gross total tumor resection
was achieved in 23 patients (82%) as assessed by early
postoperative MRI. Tumors progressed as the following
(Table 2): (1) isolated local recurrence (13 cases); (2)
local recurrence in combination with leptomeningeal dis-
semination (six cases); among the latter, in one patient,
tumor progressed as local recurrence combined with lep-
tomeningeal dissemination and seedings outside the CNS
(bone marrow and soft tissues); (3) isolated leptomenin-
geal dissemination in nine cases. Specimens from second-
ary tumors were obtained either after removal of local
progression (n = 18) or after resection/biopsy of tumor
metastases (n = 10).
Fluorescence in situ hybridization
Multicolor interphase FISH analysis of 5-m paraYn sec-
tions was performed using the following three commercial
probe sets delineating the loci of interest (Vysis, USA): (1)
dual-color probe set containing a centromere 2p11-q11
probe (spectrum orange) and a locus-speciWc 2p24/MYCN
probe (spectrum green); (2) dual-color probe set containing
a centromere 8p11-q11 probe (spectrum green) and a locus-
speciWc 8q24/MYC probe (spectrum orange); (3) multicolor
probe set containing locus-speciWc 17p13.3/LIS1 (spectrum
orange), 17q21/RARA (spectrum green), and 6q23/MYB
(spectrum aqua) probes. All FISH experiments were per-
formed in duplicate.
Pretreatment of slides, hybridization, posthybridization
processing, and signal detection were performed as previ-
ously reported [15, 20]. BrieXy, the samples showing suY-
cient FISH eYciency (>90% nuclei with signals) were
evaluated by two independent investigators. Signals were
scored in at least 200 nonoverlapping, intact nuclei.123
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a control for each probe set. Specimens were considered
ampliWed for MYCN and MYC, when more than 10% of
tumor cells exhibited either more than eight signals of the
respective oncogene probe with the reference/control ratio
>2.0 or innumerable tight clusters of signals of the locus-
speciWc probe. Gains of 6q and/or 17q were deWned as
>10% of nuclei containing three or more signals for the
respective probes, if no such Wndings were detected for the
17p locus (to rule out polyploidy). Hemizygous deletions of
6q and 17p were deWned as >50% of nuclei (mean § three
standard deviations in neoplastic controls) containing one
signal either for the 17p or for the 6q probes and ¸2 signals
of the 17q probe. No homozygous deletions were identiWed
for any of the investigated loci in this study.
Results
Pathological and clinical Wndings
On histopathological examination of primary samples, 15
tumors were diagnosed as classic MB without anaplastic
features (Table 2). In addition, nine classic MB showed pat-
terns of “mild” anaplasia, according to Eberhart et al. [3, 5].
In this small set of samples, there was no signiWcant diVer-
ence concerning progression-free survival (PFS) and over-
all survival (OS) between these two subgroups of classic
MB. The remaining four samples were identiWed as large
cell/anaplastic MB. Latter showed signiWcantly shorter
median PFS (7 months; P < 0.001) compared to classic MB
with “mild” anaplasia and those without anaplastic patterns,
whereas there were no diVerences in median PFS for classic
MB with “mild” anaplasia and for those without anaplastic
patterns (21 and 48 months, respectively; P = 0.78).
Eighteen MB recurrences (14 with classic and 4 with
large cell histology) exactly resembled the histopatholo-
gical features of their corresponding primaries. In contrast,
the remaining ten samples with classic histology in the pri-
mary tumor clearly showed anaplastic features such as
increasing nuclear pleomorphism toward either dark polyg-
onal or pale round nuclei, cell “wrapping,” elevated number
of mitoses and apoptotic bodies, and appearance of necro-
ses (Fig. 1). In two of these samples, microvascular prolif-
eration was observed in the recurrent tumor. We estimated
the cumulative incidence functions from competing risks
with respect to the acquisition of such anaplastic patterns.
Time to progression for tumors with such acquired anaplas-
tic patterns was longer when compared with samples that
showed unchanged histological appearance (Fig. 2).
Cytogenetic aberrations in primary and recurrent tumors
Totally, 84 multicolor FISH hybridizations were performed
(Table 2, Fig. 3). Among the primary tumors, 13 samples
(46%) exhibited initially balanced cytogenetic proWles for
Table 1 Clinical characteristics 
of medulloblastoma patients 
with early progression (n = 16) 
and late progression (n = 12)






Median age (years) 11.5 15 14
Range (years) 3–22 7–37 3–37
Gender
Female 5 (31%) 2 (17%) 7 (25%)
Male 11 (69%) 10 (83%) 21 (75%)
Chang stage
M0 14 (87%) 12 (100%) 26 (93%)
M1–3 2 (13%) 0 (0%) 2 (7%)
Level of resection at primary diagnosis
Gross total resection 12 (75%) 11 (92%)
Macroscopic tumor residue 4 (25%) 1 (8%)
Type of progression
Local progression 5 (31%) 8 (67%) 13 (46%)
Dissemination 6 (38%) 3 (25%) 9 (32%)
Local progression and dissemination 5 (31%) 1 (8%) 6 (21%) 
Time to progression
Median (months) 16 70 34
Range (months) 4–39 48–138 4–138
Total 16 12 28a At initial diagnosis123
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showed one or more aberrations at the loci of interest. Con-
sistent with previously published results, aberrations of
chromosome 17 were the most common Wnding aVecting
15 (54%) of the primary tumors. Concomitant loss 17p and
gain 17q indicative for isochromosome 17 [i(17q)] was
detected in 13 cases, while isolated gain of 17q was found
in two tumors. In addition, Wve samples showed either MYC
or MYCN ampliWcation, and two tumors disclosed 6q gain.
There were no tumors with 6q loss in this series of tumors
with recurrence. Comparing cytogenetic Wndings with his-
topathological data, we found that 3/4 tumors with large
cell histology showed either MYC or MYCN ampliWcations
and all of them carried i(17q). Median OS for patients,
whose tumors initially showed genomic aberrations, was
shorter than that for patients whose primaries showed
balanced proWles (43 and 128 months, respectively,
P = 0.18). Similar results were obtained for PFS. The esti-
mated median PFS for patients, whose tumors initially
showed genomic aberrations, was 18 months, whereas the
median PFS for patients whose primaries showed balanced
proWles, was 58 months (P = 0.09).
Analysis of samples from recurrent tumors disclosed an
unchanged cytogenetic proWle for the investigated loci in
19 cases (68%). Among these, six tumors were initially bal-
anced, and 13 samples already showed chromosomal aber-
rations in their primaries. In the latter 13 cases, we found no
diVerences in the extent of cytogenetic abnormalities when
primary and recurrent specimens were compared.
Seven recurrent tumors with initially balanced proWle
showed appearance of acquired cytogenetic abnormalities
involving various loci of interest. Among them, Wve tumors
Table 2 Histopathological and molecular characteristics of medulloblastoma patients at primary diagnosis and at the time of disease progression
Cases with accumulation of histological and molecular changes are indicated in bold
mts metastatic disease, LCA large cell/anaplastic histology, NA no signs of anaplasia, MA moderate anaplasia
a Case 8 also showed metastasis outside the CNS (soft tissue and bone marrow)





Primary diagnosis Progression Primary diagnosis Progression
1 4 mts LCA LCA i17q i17q
2 6 Local LCA LCA MYC; i17q; gain 6q MYC; i17q; gain 6q
3 8 Local/mts LCA LCA MYCN; gain 17q MYCN; gain 17q
4 8 mts Classic NA Classic NA i17q i17q
5 9 Local/mts Classic NA Classic NA i17q i17q
6 11 Local Classic MA Classic MA Balanced gain 17q
7 12 Local/mts Classic MA Classic MA i17q i17q
8a 15 Local/mts LCA LCA MYC; i17q; gain 6q MYC; i17q; gain 6q
9 17 Local Classic MA Classic MA Balanced Balanced
10 18 Local/mts Classic MA Classic MA Balanced gain 17q
11 18 Local Classic NA Classic NA gain 17q gain 17q
12 21 mts Classic MA Classic MA MYCN; i17q i17q
13 27 mts Classic NA Classic NA MYCN; i17q i17q
14 30 mts Classic NA Classic MA i17q i17q
15 38 Local Classic NA Classic NA Balanced Balanced
16 39 mts Classic NA Classic NA i17q i17q
17 48 Local Classic NA Classic NA Balanced Balanced
18 57 Local Classic MA LCA Balanced MYCN
19 58 mts Classic NA Classic MA Balanced balanced
20 61 mts Classic MA LCA i17q i17q
21 62 Local Classic NA Classic MA i17q i17q
22 67 Local Classic NA Classic NA Balanced Balanced
23 73 mts Classic MA LCA Balanced i17q
24 78 Local Classic NA Classic MA Balanced gain 17q; gain 6q 
25 91 Local Classic NA LCA Balanced MYCN
26 96 Local/mts Classic NA LCA Balanced gain 17q; gain 6q 
27 132 Local Classic NA Classic MA Balanced Balanced
28 138 Local Classic MA Classic MA i17q i17q123
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gain of 6q in two cases. Two other tumors with initially bal-
anced proWle disclosed appearance of MYCN oncogene
ampliWcation. Besides this, analysis of two intracranial
metastases, which developed from primaries with concomi-
tant MYCN ampliWcation and i(17q), revealed that tumor
cells bearing oncogene ampliWcation were not detected in
secondary lesions, whereas cells with i(17q) were retained.
Discussion
The concept of anaplastic MB has been expanded for clini-
cal purposes hypothesizing that even a lower degree of ana-
plasia and/or focal anaplasia may aVect patient outcome.
Most studies on the role of gradual anaplasia revealed that
even focal anaplasia had a signiWcant negative eVect on
progression-free and overall survival [3–7, 10, 13, 14].
However, some other studies showed no association
between the degree of anaplasia and MB prognosis [12,
16].
The current concept of the molecular pathogenesis of
MB suggests that these tumors have the ability to undergo
stepwise progression as it has been demonstrated for other
tumors, including neuroectodermal neoplasms [3]. The
hypothetic model of MB pathogenesis includes primary
“initiation events” (i.e. Hedgehog, NOTCH, and WNT acti-
vation) and subsequent “progression events” (i.e. chromo-
some 17 aberrations, MYC/MYCN ampliWcations, and
others). Nevertheless, this has been a hypothesis only,
because conclusive evidence of temporal molecular MB
progression has not been presented yet. Only one study
reported on CGH analyses of a single pair of primary MB
and its recurrence [6]. In that case, an increased number of
overall chromosomal aberrations was found in the recurrent
tumor, one of the acquired lesions being a deletion of 17p.
In the current study investigating 28 pairs of primary
MB and their recurrences, we found an increase in anaplastic
Fig. 1 Examples of increasing 
anaplasia in recurrent MB 
(H&E, £400). a Primary tumor 
with Homer–Wright pseudoro-
settes and no signs of anaplasia 
(Case 24). b Local recurrence of 
this tumor after 78 months with 
signs of moderate anaplasia. 
c Primary tumor with moderate 
anaplasia (Case 20). d Cranial 
metastasis of this tumor after 
61 months with severe cellular 
anaplasia. e Primary tumor with 
signs of focal moderate anapla-
sia (Case 18). f Local recurrence 
of this tumor after 57 months 
with severe diVuse anaplasia123
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mately 40% of tumors. Notably, the time to progression
was longer for tumors with increasing degree of anaplasia
in the recurrence, suggesting that a certain interval is
required for gradual accumulation of such changes within
the histological appearance. To test the likelihood of molec-
ular progression in MB, we analyzed Wve chromosomal loci
that have been reported to be crucial for MB biology and
prognosis [2, 6–9, 11, 13, 15, 17, 18, 23–25]. We found that
patients bearing primary tumors with characteristic chro-
mosomal aberrations such as MYC or MYCN oncogene
ampliWcation, 17q gain, or 6q gain had a shorter median
PFS and OS, suggesting that tumor cells with these chro-
mosomal abnormalities represent cytological sources for
selective growth advantage underlying further clinical pro-
gression per se. These Wndings are exactly in line with our
results obtained from larger series of MB [19].
MYCN ampliWcation is a hallmark of tumors with poor
clinical outcome [13, 19]. Intriguingly, two MB showed
unexpected loss of cells bearing MYCN ampliWcation
within their intracranial metastatic deposits. Metastatic
lesions have been widely thought to arise from a small
selected fraction of cells in the primary tumor, which share
molecular alterations associated with loss of cell adhesion
and increased cell motility. Perhaps, MYCN ampliWcation
has no eVects on the capability of MB cells to disseminate
throughout the CNS. However, this alteration seems to
induce locally aggressive behavior, as we found acquired
Fig. 2 Cumulative incidence of tumor progression for tumors with ac-
quired anaplastic features in the recurrent tumor and for those without.
Time to progression was considerably longer for patients whose recur-
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Fig. 3 Acquired cytogenetic aberrations in progressed MB detected
by FISH analysis. a Case 26, primary tumor: balanced proWle for chro-
mosomal loci 17p13 (red), 17q21 (green), and 6q23 (blue) with two
signals for each probe. b Local progression of this tumor after
96 months: appearance of 17q21 and 6q gains (three and more signals).
c Case 25, primary tumor: balanced proWle for chromosomal loci 2p24/
MYCN (green) and 2p11-q11 (red) with two signals for each probe.
d Local progression of this tumor after 91 months: appearance of
MYCN oncogene ampliWcation (numerous green signals and signal
clusters)123
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removed 5 and 7.5 years after the primary operation,
respectively. To our knowledge, this is the Wrst report on
postponed oncogene ampliWcations in MB progression.
Interestingly, both these tumors showed local tumor pro-
gression, but no signs of metastatic disease (Table 2).
Undoubtedly, the analysis of two cases only allows for
careful general conclusions. Nevertheless, these Wndings
appear to be intriguing and further analysis of genetic alter-
ations associated with MB dissemination is warranted.
Five of 13 tumors (38%), whose primaries disclosed bal-
anced proWles for all investigated loci, showed acquired
anomalies of chromosome 17, accompanied by gains of 6q
in two tumors. Notably, cases with isolated gain of 17q
(without concomitant deletion of 17p) prevailed in this
group (four out of Wve), whereas i(17q) comprised the vast
majority of abnormalities detected in primary tumors (13
out of 15 tumors). These Wndings strongly support the
notion that i(17q) may represent a unique primary chromo-
somal aberration in a subset of MB [3, 15, 18]. On the con-
trary, isolated gain of chromosome 17q appears to be a
centrally important aberration for the development of meta-
static disease. This is in line with our recent demonstration
of isolated gain of 17q being associated with unfavorable
prognosis, whereas isolated 17p deletion is not [19].
In general, all our Wndings indicate that sequential chro-
mosomal aberrations of the type seen in other neuroecto-
dermal tumors can occur in MB as well. Nevertheless, it
remains uncertain whether these cytogenetic abnormalities
are already intrinsically present in a small (and accordingly
“invisible”) fraction of primary tumor cells with their
sequential clonal expansion after treatment or accumulated
over time in a stepwise cytogenetic fashion.
In conclusion, we found that MB can undergo temporal
molecular progression with accumulation of “prognosti-
cally unfavorable” cytogenetic changes, including even
acquisition of oncogene ampliWcations. Thus, treatment
failures after standard combined treatment of MB patients
may, at least in part, be caused by acquired and steady pro-
gressing changes in tumor biology, especially in tumors
showing late recurrence. Particularly, when considering tar-
geted therapy approaches for relapsed patients, secondary
biopsy should be performed to assess the biologic proper-
ties of the recurrent tumor, which may diVer substantially
from the primary tumor.
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